Literature DB >> 21161014

Effect of mycophenolate mofetil plus adriamycin on HepG-2 cells.

Yan-Kui Chu1, Yi Liu, Ji-Kai Yin, Nan Wang, Liang Cai, Jian-Guo Lu.   

Abstract

AIM: To investigate the influence of mycophenolate mofetil (MMF) plus adriamycin (ADM) on hepatocellular carcinoma (HCC) cells.
METHODS: HCC cells were treated with 100 μg/ml of MMF alone (MMF group), 1 μg/mL of adriamycin (ADM group) alone, or a combination of the drugs (MMF + ADM group). We performed an 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) assay to measure the growth inhibition rate of HCC cells. Flow cytometry was used to determine the percentage of cells in different phases of the cell cycle and the number of apoptotic cells. Hoechst 33258 staining revealed the morphological changes associated with apoptosis in HCC cells.
RESULTS: The results of MTT assays revealed that monotherapy with ADM or MMF showed inhibition of cell growth, while MMF + ADM therapy afforded an inhibition rate of more than 90% with cell distribution in G1 and G2/M phase greater than that in S phase. MMF + ADM treatment also downregulated Bcl-2 expression markedly. The growth of HCC cells was markedly inhibited and apoptosis was enhanced in all the 3 groups. Compared with other 2 groups, the MMF + ADM group showed more obvious apoptosis of cells.
CONCLUSION: The MMF plus ADM combination exerts remarkable inhibitory effects on the growth of HCC cells.

Entities:  

Keywords:  Adriamycin; Apoptosis; Cell cycle; Hepatocellular carcinoma; Mycophenolate mofetil

Year:  2010        PMID: 21161014      PMCID: PMC2998975          DOI: 10.4254/wjh.v2.i8.311

Source DB:  PubMed          Journal:  World J Hepatol


  10 in total

1.  Regression of post-transplant Kaposi sarcoma after discontinuing cyclosporin and giving mycophenolate mofetil instead.

Authors:  M M Hussein; J M Mooij; H M Roujouleh
Journal:  Nephrol Dial Transplant       Date:  2000-07       Impact factor: 5.992

2.  Cyclosporine A, FK-506, 40-0-[2-hydroxyethyl]rapamycin and mycophenolate mofetil inhibit proliferation of human intrahepatic biliary epithelial cells in vitro.

Authors:  Chao Liu; Thomas Schreiter; Andrea Frilling; Uta Dahmen; Christoph E Broelsch; Guido Gerken; Ulrich Treichel
Journal:  World J Gastroenterol       Date:  2005-12-28       Impact factor: 5.742

Review 3.  Role of adjuvant treatment in liver transplantation for advanced hepatocellular carcinoma.

Authors:  D Cherqui
Journal:  J Hepatobiliary Pancreat Surg       Date:  1998

4.  Cloning of a bcl-2 homologue by interaction with adenovirus E1B 19K.

Authors:  S N Farrow; J H White; I Martinou; T Raven; K T Pun; C J Grinham; J C Martinou; R Brown
Journal:  Nature       Date:  1995-04-20       Impact factor: 49.962

Review 5.  Therapeutic drug monitoring of non-anticancer drugs in cancer patients.

Authors:  M Joerger; J H M Schellens; J H Beijnen
Journal:  Methods Find Exp Clin Pharmacol       Date:  2004-09

6.  Rapamycin inhibits cell growth by induction of apoptosis on hepatocellular carcinoma cells in vitro.

Authors:  Jun-Feng Zhang; Jia-Jun Liu; Min-Qiang Lu; Chang-Jie Cai; Yang Yang; Hua Li; Chi Xu; Gui-Hua Chen
Journal:  Transpl Immunol       Date:  2007-01-16       Impact factor: 1.708

7.  Anti-tumor activity of mycophenolate mofetil against human and mouse tumors in vivo.

Authors:  R J Tressler; L J Garvin; D L Slate
Journal:  Int J Cancer       Date:  1994-05-15       Impact factor: 7.396

8.  Low recurrence rate of hepatocellular carcinoma after liver transplantation: better patient selection or lower immunosuppression?

Authors:  Marco Vivarelli; Roberto Bellusci; Alessandro Cucchetti; Giulia Cavrini; Nicola De Ruvo; Ardo Abdiueli Aden; Giuliano La Barba; Stefano Brillanti; Antonino Cavallari
Journal:  Transplantation       Date:  2002-12-27       Impact factor: 4.939

Review 9.  Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation.

Authors:  Markus Guba; Christian Graeb; Karl-Walter Jauch; Edward K Geissler
Journal:  Transplantation       Date:  2004-06-27       Impact factor: 4.939

10.  Mycophenolate mofetil modulates adhesion receptors of the beta1 integrin family on tumor cells: impact on tumor recurrence and malignancy.

Authors:  Tobias Engl; Jasmina Makarević; Borna Relja; Iyad Natsheh; Iris Müller; Wolf-Dietrich Beecken; Dietger Jonas; Roman A Blaheta
Journal:  BMC Cancer       Date:  2005-01-11       Impact factor: 4.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.